Pınar ÖZMEN YILDIZ, Ebubekir AKSU, İsmail GÜRBAK, İbrahim YILDIZ

Rivaroksabana bağlı spontan hemotoraks olgusu

Valvüler olmayan atriyal fibrilasyonlu hastalarda tromboembolik korunma için varfarine alternatif olarak yeni oral antikoagülanlar ortaya çıkmıştır. Yeni oral antikoagülanlar varfarine göre daha iyi uyum ve güvenlik marjına sahip olmakla birlikte, kullanımları konusunda dikkatli olmalıyız. Bu yazıda, rivaroksaban tedavisine bağlı bir spontan hemotoraks olgusu sunuldu. Araştırmamıza göre, rivaroksaban tedavisine sekonder ilk spontan hemotoraks olgusu budur.

A case of rivaroxaban associated spontaneous hemothorax

New oral anticoagulants have emerged as an alternative forwarfarin for thromboembolic prevention in patients with nonvalvularatrial fibrillation. Although new oral anticoagulantshave better compliance and safety margin compared to warfarin,we must be cautious with their usage. In this article, wereport a case of spontaneous hemothorax related to rivaroxabantreatment. According to our research, this is the first case ofspontaneous hemothorax secondary to rivaroxaban treatment.

PDF

___

1. Patrini D, Panagiotopoulos N, Pararajasingham J, Gvinianidze L, Iqbal Y, Lawrence DR. Etiology and management of spontaneous haemothorax. J Thorac Dis 2015;7:520-6.
2. Azfar Ali H, Lippmann M, Mundathaje U, Khaleeq G. Spontaneous hemothorax: a comprehensive review. Chest 2008;134:1056-65.
3. Lafçi G, Kocabeyoglu SS, Yalcinkaya A, Kadirogulları E, Turkvatan A, Ozatik MA. Rupture of isolated inferior thyroid artery aneurysm leading to life-threatening hemothorax. Turk Gogus Kalp Dama 2013;21:445-7.
4. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
5. Brem E, Koyfman A, Foran M. Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians. J Emerg Med 2013;45:143-9.
6. Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects. Int J Clin Pharmacol Ther 2007;45: 335-44.
7. Helin TA, Pakkanen A, Lassila R, Joutsi-Korhonen L. Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories. Clin Chem 2013;59:807-14.
8. Çiledağ A, Çelik G, Köycü G, Gürsoy E, Yüksel C. A rare complication of oral anticoagulant treatment: hemothorax. [Article in Turkish] Tuberk Toraks 2012;60:70-3.
9. Nasiłowski J, Krenke R. Hemothorax with high number of eosinophils following warfarin overdose. Pneumonol Alergol Pol 2002;70:496-503. [Abstract]
10. Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010;70:703-12.
11. Graff J, Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet 2013;52:243-54.